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1.1. Soft-tissue sarcoma 
1.1.1.   Epidemiology and incidence 
Soft-tissue sarcomas (STSs) are malignant tumors arising from nonepithelial 
extraskeletal tissue of body except from the reticuloendothelial system, glia and supporting 
tissue of various parenchymal organs [1]. They comprise a group of more than 50 histological 
entities [2]. The term sarcoma does not, unfortunately, indicate the likehood or rapidity of 
metastasis. It is therefore important to further qualify that as “well differentiated” or “poor 
differentiated” based on histological features [1].  
 STSs are rare tumors with an estimated annual incidence around 30 new cases per 
1,000,000 of population annually [3-6]. They comprise only 0.5-1% of all cancer types [7]. In 
children, the incidence of STS is relatively higher, at 1-3%, but cancer is not a common 
disease of childhood. Like other malignancies, STS becomes more common with increasing 
age, with 65 years being the median age of diagnosis [4,5,8]. The age-related incidence vary 
among the different histological subtypes, with embryonal rhabdomyosarcoma occurring 
almost exclusively in children, synovial sarcoma affecting young adults, while pleomorphic 
high grade sarcoma, liposarcoma and leiomyosarcoma dominates in the elderly (Figure 1) [1].  
 
 
Figure 1. Approximate relation of age to incidence of various types of sarcoma. From Weiss SW, 
Goldblum R: Enzinger & Weis's Soft Tissue Tumors, 5th edn. Philadelphia: Mosby, Elseiver Inc; 







The age-adjusted incidence rates of STSs in Norway have shown a slight increase the 
last 50 years since registration started (Figure 2), recorded at 3,2 in 2009 [5]. 
 
Figure 2. Age-adjusted incidence rates of STSs in Norway, 1954 to 2004. From NORDCAN: Cancer 
Incidence, Mortality, Prevalence and Survival in the Nordic Countries, Version 5.0. Association of the 
Nordic Cancer Registries[8]. Permission obtained from The Cancer Registry of Norway. 
 
For the Russian Federation, this figure was 2,3 for 2007, but specifically in 
Arkhangelsk region, where our research material was partly gathered from, it was 3,6 per 
100,000 [4]. 
The incidence of STS is increasing with increasing age and is approximately the same 
for male and female patients with the exception of a drop in incidence in females during their 





Figure 3. Age-specific incidence rates of STSs in Norway per 100 000, 1954 to 2004. From 
NORDCAN: Cancer Incidence, Mortality, Prevalence and Survival in the Nordic Countries, Version 
5.0. Association of the Nordic Cancer Registries[8]. Permission obtained from The Cancer Registry of 
Norway. 
 
The mortality of STSs remains high at 30-40%, making STS one of the more unfavorable 
forms of cancer to contract [3-5]. In Norway, the survival has gradually increased in the last 
50 years from 30-40% five-year survival during the sixties to a much better 60-70% survival 
after 1990 (Figure 4). Some of this survival benefit has come from new and better treatment 
protocols for childhood STSs giving the younger age-groups a better overall prognosis [9]. 
Even so, the prognosis in the adult population has also increased, maybe because of better and 
earlier diagnosis through increased awareness in the population and novel diagnostic methods 









Figure 4. Age-standardized relative survival of STSs in Norway, all ages. From NORDCAN: Cancer 
Incidence, Mortality, Prevalence and Survival in the Nordic Countries, Version 5.0. Association of the 
Nordic Cancer Registries[8]. Permission obtained from The Cancer Registry of Norway. 
 
1.1.2.   Histopathology 
STSs are usually classified according to their resemblance to normal mature 
mesenchymal tissues [1]. However, high grade lesions lose gradually resemblance with the 
tissue of derivation. Moreover, some sarcomas have no obvious normal counterpart and 
belong therefore to a class of tumors of uncertain differentiation. Taking in consideration the 
rarity and variability of sarcomas, they often represent a diagnostic challenge for a 
pathologist, who in many cases have to give a pathologic diagnosis based on a marginally 
sized biopsy [2].  
According to the current World Health Organization’s classification of tumors of soft 
tissue and bone, there are nine main groups of STSs (Appendix I) [2]. High grade 
pleomorphic sarcoma, liposarcoma, leiomyosarcoma, synovial sarcoma and malignant 
peripheral nerve sheet tumors (MPNST) are the most common STS subtypes comprising 
approximately 75 percent of the annual STS incidence [2,7,8]. Some examples of major STS 









Figure 5. Examples of major STS types. A, Undifferentiated pleomorphic sarcoma; B, Round 











Figure 5 (continued). Examples of major STS types. C, Leiomyosarcoma; D, Biphasic synovial 









Figure 5 (continued). Examples of major STS types. E, Malignant peripheral nerve sheath tumor 







 When conducting studies on STS it appears that some specific sarcomas differ greatly 
from others and should be excluded/investigated on their own. This is particularly the case for 
skin-sarcomas, gastrointestinal stroma tumors (GISTs), embryonal rhabdomyosarcoma in 
children and Ewing/peripheral neuroectodermal tumor (PNET) sarcomas as these have their 
own tailored treatments [9,11,12].  
 
1.1.3.   Pathogenesis 
The pathogenesis of most STS is still unknown [1]. Nevertheless, there are some 
recognized causes, which are listed below. It is important to mark that, unlike carcinomas, an 
origin of sarcomas from benign soft tissue tumors is exceedingly rare; virtually the only 
exclusion is MPNST, frequently arising in neurofibroma in patients with Von 
Recklinghausen’s neurofibromatosis [13]. 
 
1.1.3.1.  Hereditary sarcoma 
A number of syndromes are associated with STS development. Syndromes able to 
induce STSs are most often due to mutations in tumor suppressor- , growth factor- and growth 
factor receptor genes and translocations forming new potent fusion-genes and proteins [14]. 
The list of most common cancer syndromes leading to STS includes Li Fraumeni, 
neurofibromatosis type I (Von Recklinghausen’s) and type II, familial adenomatous polyposis 
(FAP)/Gardner, Retinoblastoma, Werner, Lynch syndromes and tuberous sclerosis/Burneville 
disease among others [14]. This list will undoubtedly lengthen with increasing understanding 
of the molecular underpinnings of mesenchymal neoplasia [1]. 
 
1.1.3.2.  Environmental factors 
Among the environmental factors implicated in the development of STSs, trauma is 
most frequently mentioned. It is now clear, however, that trauma often seems to be an event 
that merely calls attention to the underlying neoplasm, though there are relatively many well 
documented reports of STS plainly linked to trauma [1,15]. Other factors include asbestosis 
relating to mesotheliomas [16], uptake of chlorophenols, especially belonging to dioxin group 




exposure resulting in rare cases of postradiation sarcoma, which in the majority of cases is 
represented by pleomorphic undifferentiated sarcoma [21]. In addition, there is an increased 
risk of subsequent sarcoma in survivors of childhood cancers such as leukemia, 
retinoblastoma, Wilms’s tumor, Hodgkin’s lymphoma and neuroblastoma [22,23]. 
 
1.1.3.3.  Oncogenic viruses and immunologic factors 
Kaposi’s sarcoma is closely linked to infection with human herpes virus 8 (HHV8). 
However, very few healthy individuals infected with HHV8 develop Kaposi’s sarcoma, but in 
immunocompromised individuals many of those with previous HHV8 infection will develop 
Kaposi’s sarcoma [24,25]. There is also a large body of literature, supporting the role of 
Epstein-Barr virus in the pathogenesis of leiomyosarcoma in patients with suppressed 
immunity [26,27]. In Stewart-Treves syndrome, angiosarcomas can arise in the setting of 
chronic lymphedema secondary to radical mastectomy [28,29], which is often explained by 
the loss of regional immune surveillance.  
 
1.1.4.   Diagnostics 
Most patients with suspected sarcoma present with a growing, painless extremity 
lump. Pain is reported in only about one third of cases. Because of mostly painless 
presentation, the diagnosis of STS is often delayed. Late diagnosis of patients with 
retroperitoneal sarcomas is especially common because of the large retroperitoneal space, 
generally slow growth rate, and the tendency of sarcomas to gradually displace rather than to 
invade adjacent tissues [30]. 
In Scandinavia, patients presenting with a superficial tumor or lump >5 cm in greatest 
diameter or deep tumor irrespective of size, should be referred to a sarcoma center as soon as 
possible and prior to any surgical intervention [31]. All patients with suspected sarcoma are 
subjected to imaging procedures in order to establish the extent of the tumor and to determine 
the type of surgical procedure needed. Both normal skeletal x-ray, CT and MRI are used, 
although MRI gives the best impression of the soft tissues and therefore is the imaging 
modality of choice [32,33]. In recent years positron emission tomography (PET) scans have 
become popular and its use has been implemented in the diagnostics for many types of cancer. 




a supplement to MRI [34]. PET-scans are as of today more efficiently used to detect local 
recurrence after the completed therapy [34].  
The necessity of pretreatment biopsy is a topic of discussion due to the risk of possible 
tumor contamination with further possible recurrence in the needle track after a core biopsy 
[35]. In Norway, a biopsy is recommended only in cases where initial wide resection is not 
feasible. However this point is not universally shared, since such recurrences are extremely 
rare [1]. The biopsy is used to determine the histological type and malignancy grade, and 
together with imaging procedures also the stage of the tumor.  
 
1.1.5.   Prognostic factors 
1.1.5.1.  Grading 
Since the first grading system for sarcomas was introduced by Broders et al. in 1939, a 
number of systems have been utilized in sarcoma diagnostics [36]. Several parameters have 
been used to grade sarcomas, such as cellular pleomorphism, cellularity, mitotic index, 
vascular invasion, tumor necrosis, surgical site, nuclear atypia, histologic type and subtype, 
tumor size and tumor differentiation [37,38]. The WHO manual on the Pathology and 
Genetics of Tumors of Soft Tissues and Bone recognizes two grading systems used on STS; 
the FNCLCC and the NCI grading systems, respectively [2].  
The FNCLCC grading system, reviewed in Coindre 2006 [37], is calculated from 
tumor differentiation, mitotic count and tumor necrosis. Tumor differentiation and mitotic 
count are given a score from 1-3 and tumor necrosis is scored as 0-2 [1,2,36-39]. The 
histologic grade is derived from the total score with 2-3 being grade 1, 4-5 being grade 2 and 













Table 1. Definitions of grading parameters for the FNCLCC system.  
 
From Weiss SW, Goldblum R: Enzinger & Weis's Soft Tissue Tumors, 5th edn. Philadelphia: Mosby, 
Elseiver Inc; 2008[1] Permission obtained from Elseiver Inc. 
 
The NCI grade is derived from the histologic type or subtype and histopathological 
parameters including necrosis (the most important), cellularity, pleomorphism and mitosis as 
described by Costa et al. in 1984 and modified in 1990 [40,41]. 
In a comparative study of 410 patients diagnosed with STS, Guillou et al. found the 
FNCLCC grading system to be marginally better at predicting metastasis and disease-specific 
survival (DSS) compared to the NCI grading system [1,38]. However, both systems yielded 
prognostic groups and are recognized in the WHO manual as suitable for grading STSs [2].  
In addition to these well recognized systems both two-, and four-tiered (as in case of 
SSG) systems exist [38]. In Table 2, a proposed conversion between two-, three- and four-







Table 2: Conversion table between different grading systems for Soft Tissue Sarcomas 
Two-tiered system Three-tiered systems Four-tiered systems 
Low grade Grade 1 Grade 1 
  Grade 2 
High grade Grade 2 Grade 3 
 Grade 3 Grade 4 
Adapted from The WHO Classification of Tumors: Pathology and Genetics oft Tumors of Soft Tissue 
and Bone [2] Permission obtained from WHO IARC. 
The three-tiered systems are considered most suitable for predicting survival and 
likelihood of treatment response, since they are able to predict the behavior of both low-grade, 
intermediate-grade and high-grade tumors, which seems to be well defined categories of 
STSs. Nevertheless, the recently proposed new system, termed SIN by the SSG group, 
anticipated promising binary stratification which would help to simplify treatment strategy 
scheme [38,42]. The system uses three factors, namely Size, vascular Invasion and Necrosis 
in a dichotomous fashion (size < or > 8 cm, and +/– vascular invasion and necrosis). The low-
risk group (score 0-1) had an 81% 5-year survival compared to the high-risk group (score 2-3) 
with a 5-year survival of 32%.  
 
1.1.5.2.  Staging 
STSs are typically staged according to the tumor, nodule, grade and metastasis 
(TNGM) system developed by the American Joint Committee on Cancer (AJCC) and the 
International Union Against Cancer (UICC) as devised by Russel et al. in 1977 and later 
revised and currently published in the AJCC Cancer Staging Manual 7
th
 edition [43,44]. The 
TNGM system for STSs includes tumor size, nodal metastasis, malignancy grade and distant 
metastasis to give a stage ranging from I-IV. The system is designed to include two-, three- 
and four-tiered grading systems using a conversion table (Table 1). Table 3 summarizes the 








Table 3: Clinical staging and survival of Soft Tissue Sarcoma according to the tumor, node, 
grade and metastasis system 
Stage Tumor Node Metastasis Grade Definition 
T1a N0 M0 G1, GX Ia 
T1b N0 M0 G1, GX 
T2a N0 M0 G1, GX Ib 
T2b N0 M0 G1, GX 
T1a N0 M0 G2, G3 IIa 
T1b N0 M0 G2, G3 
T2a N0 M0 G2 IIb 
T2b N0 M0 G2 
T2a, T2b N0 M0 G3 III 
Any T N1 M0 Any G 
IV Any T Any N M1 Any G 
T1: Tumor ≤5cm in greatest 
dimension 
T1a: Superficial tumor 
T1b: Deep tumor 
T2: Tumor>5cm in greatest 
dimension 
T2a: Superficial tumor 
T2b: Deep tumor 
N1: Regional lymph node 
metastasis 
M1: Distant metastsis 
G: Histological grade 
Adapted from AJCC: Soft tissue sarcoma. In: Edge SB, Byrd DR, Compton CC, et al., eds.: 
AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer, 2010, pp 291-8.[44] 
Permission obtained from Springer. 
 In 2002, Kattan et al. published the Memorial Sloan-Kettering Cancer Center 
(MSKCC) nomogram for 12-year sarcoma-specific death in which they utilized a subset of 
independent prognostic markers to predict the clinical cancer development [45,46]. This 
approach has later been adapted for several clinical situations (pre-/post-operative, after 
recurrence etc.) and for specific subsets of patients (specific sites and histology etc.) [47-49]. 
If developed and used correctly, these nomograms seem to be better able to predict the 
clinical course of the individual patient than the conventional staging systems [50]. 
 
1.1.5.3.  Vascular invasion in STS 
Vascular invasion represents a well established prognostic factor in several tumor 
types, including malignant melanoma, papillary thyroid cancer, endometrial cancer, and 
testicular cancer. In STS, vascular invasion has repeatedly shown prognostic value [51-53], 
but it is generally not applied systematically in pathological evaluations. However, it is 
considered as one of three major prognostic factors in the SIN system, elaborated by SSG 




within any space having an obvious endothelial lining. Such tumor cells have to be either 
adherent to the luminal aspect of the vessel wall or, if free-floating, associated with adherent 




Figure 6. Vascular invasion in STS. A, Tumor cells have direct contact with blood stream 
in this example of malignant peripheral nerve sheath tumor. The present study material, 




Consistently, our univariate analysis (Figure 6B) demonstrated that vascular invasion 
in STS correlated distinctly with higher disease specific mortality rates in the whole patients 
cohort. In the multivariate analysis, however, vascular invasion was not an independent 
significant variable as it co-varied with FNCLCC grade. 
 
1.1.5.4.  Other prognosticators in STS 
Primary tumor location has been previously reported as an important prognostic 
marker in STS, with head and neck as well as retroperitoneal location greatly increasing STS-
specific mortality [46,54].  
Traditionally, the specific histopathologic subtype has been considered to be of 
secondary importance because of the common impression that individual histologic subtypes 
of comparable histologic grade behave similarly [54,55]. However, several reports have 
established the independent adverse prognostic significance of specific histologic subtypes 
[56,57]. Our data could not prove the observation that different high-grade sarcomas possess 
different biological behaviors.  
Several studies suggest that margin positivity is a marker of adverse prognosis. For 
instance, the MSKCC group reported in 2002 [58] that a positive microscopic margin was 
associated with a 1.6-fold increase in sarcoma-related death. Our current data further support 
these observations; in the multivariable analysis, margin positivity was associated with a 2.9-
fold increase in STS-related death (P<0.001). 
  Other clinical factors reported as a prognosticator in STS include local and distant 
recurrence [45], and nodal status [59,60].  
Specific molecular prognostic markers may be particularly useful in our epoch of new 
insight into the molecular biology of cancer. The detection of such markers could potentially 
be based on high-throughput assays.  
 
1.1.6.   Treatment 
1.1.6.1.  Surgery 
Surgery with wide resection margins is the main method of treatment of STS patients 
[33]. There is ample evidence suggesting that surgery should be planned and executed at a 




surgery or after finding STS in lesions thought to be benign before surgery, have greater 
chance for recurrence than patients treated with primary definite surgery [61,62]. 
 Classically, amputation was required for adequate resection margins in extremity STS 
but in the last twenty years limb-sparing surgery has emerged as a good alternative to 
amputation with significantly less morbidity for the patients as a result [63,64]. A recent study 
in extremity STS suggest that for tumors ≤ 3 cm in largest diameter surgery alone is adequate 
therapy [65]. For larger tumors, and small tumors with marginal or uncertain resection 
margins, combinations with radiotherapy and/or chemotherapy are common [33]. 
For trunk, head and neck, visceral and retroperitoneal locations, surgery with wide 
resection margins is also the treatment modality of choice. However, it is frequently a 
challenge to obtain wide resection margins for these locations and combinations with other 
treatment modalities are often warranted [66,67]. 
 
1.1.6.2.  Chemotherapy 
Pre- and postoperative chemotherapy is broadly used in treatment of bone sarcomas 
[68]. In STS its usage is a bit of a controversy as there have been conflicting reports regarding 
the effect of such treatment [69]. The “Soft Tissue Sarcomas: ESMO clinical 
recommendations for diagnosis, treatment and follow-up” assess adjuvant chemotherapy as 
not standard treatment, but an option in cases of large or high grade tumors [32].  
Doxorubicin and Ifosfamide containing regimes are used both for adjuvant and for 
neoadjuvant treatment of advanced STS [70-72]. Novel drugs as gemcitabine and taxans, 
among others, are also used [10,73]. Additionally, Trabectidin® was recently approved by 
FDA for palliative STS treatment [74]. 
Neoadjuvant chemotherapy is used for inoperable STS to shrink the tumor hopefully 
leading to a possible wide resection and elimination of subclinical disease [75]. Isolated limb 
perfusion and hyperthermic isolated limb perfusion are novel techniques available in some 
cancer centers for the treatment of primary unresectable extremity STS, that renders the 






1.1.6.3.  Radiotherapy 
Adjuvant radiotherapy is warranted where initial resection yields uncertain, marginal 
or intralesional resection margins [79,80]. The dosages are typically between 50 and 75 Gy, 
and higher radiation doses (63 Gy or more) yield superior tumor control and survival [81]. A 
rise in complications occurs in patients who receive doses of 68 Gy or more, which provides a 
therapeutic window for benefit in these patients [81]. For STS of other sites, adjuvant 
radiotherapy remains controversial [66,82].  
Intensity-modulated radiation therapy (IMRT) is an advanced mode of high-precision 
radiotherapy that utilizes computer-controlled linear accelerators to deliver precise radiation 
doses to a malignant tumor or specific areas within the tumor. Several studies showed 
recently that IMRT can be administered safely and with promising efficacy, especially in 
patients with locally advanced STS [82,83] 
Primary radiotherapy is mostly used in cases where surgery is not possible and the 
effect is difficult to screen as these tumors often have a dismal prognosis [84]. 
 
1.2.   Molecular-genetic abnormalities in sarcomas 
The molecular-genetic background of cancer is a hotspot of nowadays’ research. Most 
of STS carry complex, but non-specific karyotypes, with numerous gains and losses [85], 
while approximately 15-20% of them, namely Ewing sarcoma, synovial sarcoma, and 
myxoid/round cell liposarcoma, have specific translocations and relatively simple caryotypes 
[86]. In addition, a minority of tumors carry specific somatic gene mutations, like c-kit or 
PDGFR-α mutations in GIST. The target genes, both for the reciprocal translocation fusion 
products, for instance EWSR1-ETS in Ewing sarcoma, and random mutations, code for 
hybrid oncoproteins which act as aberrant transcription factors, stimulating several 
intracellular signaling pathways and resulting in cell proliferation, evasion of growth 
inhibition, escape from senescence and apoptosis, induction of angiogenesis, invasion and 
metastasis [87].  
The above-mentioned essential mechanisms of carcinogenesis were proposed in 2000 
and considerably upgraded in 2011 by Hanahan and Weinberg [88,89]. Each of these 
mechanisms is regulated by several intracellular signaling pathways which further interact in 




aberrations are more likely to influence the clinical behavior of a malignant tumor, including 
invasion and metastasis.  
 
1.2.1.   Tumor differentiation and EMT 
Tumor differentiation is a term used to describe the appearance of malignant tumor. It 
can be defined as the extent to which a tumor resembles its tissue of origin. Well-
differentiated tumors resemble closely their tissue of origin, whereas poorly-differentiated 
tumors barely resemble their tissue of origin. The lack of differentiation, also called anaplasia, 
is characterized by a number of histological features, such as pleomorphism, which can be 
defined as variation in cell size and shape; nuclear hyperchromasia due to abundance of DNA, 
i.e. polyploidy; and loss of cellular polarity and adhesion [90]. The sense of these changes is 
to provide the tumor cell by motility, which, in turn, augments tumor’s capability to invade 
and metastasize.  
In epithelial tumors, such change in cellular shape from original to spindle, or stellate, 
associated with loss of polarity and intercellular contact, upregulation of mesenchymal 
markers with gain of invasive behavior is frequently referred to as epithelial-to-mesenchymal 
transition (EMT). EMT is defined as a sequence of protein modifications and transcriptional 
events in response to a certain set of extracellular stimuli leading to a stable, but sometimes 
reversible, cellular change [91]. This concept, though, is not universally supported [92]. 
Multiple molecular mediators of EMT have been described in carcinomas [93]. The 
list of EMT pathways includes nuclear factor-kappa B (NF-κB), AKT/mammalian target of 
rapamycin (AKT/mTOR) axis, mitogen-activated protein kinase (MAPK), beta-catenin, 
protein-kinase C (PKC) and others [94]. However, STSs are already mesenchymal tumors, 
and expression of markers linked to EMT does not support EMT as a biological event in 
them. Moreover, the markers linked to EMT have clearly defined roles in tumor biology that 
are distinct from EMT, and the negative impact of these factors on tumor behavior can rather 
be defined as “dedifferentiation” or “anaplasia” in STS.  
 
1.2.2.   Tumor proliferation and growth 
Tumor proliferation can be defined as an increase in tumor cell number due to altered 




differentiation. Abnormal cell proliferation is necessary, although often insufficient, for 
tumorigenesis. The rate of tumor cell proliferation depends on the rate of cell division, the 
fraction of cells within the population undergoing cell division (growth fraction), and the rate 
of cell loss from the population due to terminal differentiation or apoptosis. This is important 
since the goal of most current cancer therapy strategies is to reduce the number of tumor cells, 
to prevent their further accumulation and to be antiproliferative by nature. 
The growth fraction of a tumor can be registered by several techniques. The easiest 
and most used method is the mitotic count under light microscopy, which is incorporated in 
several STS grading systems, including FNCLCC system [2,38]. Beside the advantages, 
this method has some drawbacks such as high intra- and interobserver variability and 
subjective estimation. This can be avoided by the use of immunohistochemical markers of 
proliferation like Ki-67 or MIB-1 [95,96]. Other methods of measuring the proliferation rate 
are detection of cells undergoing DNA synthesis [97], flow cytometry to estimate the 
percentage of cells in S-phase, and the detection of cycle-linked markers.  
The transition between cell cycle phases is regulated by checkpoints which, in turn, 
requires an expression of a variety of proteins, including regulating cyclin-dependent kinases 
(CDKs), regulatory proteins and transcription factors like Ras oncogene, retinoblastoma 
tumor-suppressor protein (Rb), and growth factors as platelet-derived growth factor (PDGF), 
transforming growth factor beta (TGF-β), insulin-like growth factor (IGF-1) and many others 
[98-101]. Many of these are known molecular biomarkers and current subjects of research 
both in epithelial tumors and in STS. 
 
1.2.3.   Molecular markers 
Molecular markers are biological molecules found in blood, other body fluids, or 
tumor tissue [102]. They can be divided into diagnostic, predictive and prognostic markers, 
helping, respectively, to establish more accurate and definitive diagnoses, predict response to 
specific therapies, and finally, predict survival. 
There can be considerable overlap for a marker’s role across functional categories. For 
instance, an immunohistochemical testing of tumor tissue for female steroid hormone 
receptors can be used both as a diagnostic procedure in differential diagnostics of metastasis 
and as a predictor of tamoxifen or aromatase inhibitor therapy success in breast cancer. In 




cancers [103,104]. Molecular markers may offer great promise in the care of cancer patients 
especially with respect to individual, tailored cancer treatment [105,106]. 
  
1.2.4.   Markers of tumor growth, proliferation and differentiation 
1.2.4.1.  TGF-β 
TGF-β is a family of 3 highly homologous proteins, called TGF-β1, TGF-β2 and TGF-
β3, which have very similar functions. They all are known to induce G1 arrest in order to 
terminate proliferation, induce differentiation, or promote apoptosis in normal cells, thus 
being a natural tumor-suppressive agent. However, in tumorigenesis, this mediator initiates 
dedifferentiation through activation of SMAD and non-SMAD (DAXX) signalling pathways 
[107]. This pro-neoplastic action becomes possible through either blockade of the TGF-β 
pathway with receptor-inactivating mutations, or selective inactivation of the tumor-inhibiting 
arm of this pathway [108]. Another possibility is TGF-β induced systemic immune 
suppression [109]. The TGF-β pathway activation has been shown to negatively influence 
prognosis in both epithelial [110,111] and in mesenchymal bone [112] and soft tissue tumors 
[113-115]. The most of studies, however, are devoted to one particular STS type, while 
investigations of TGF-β1 expression by whole-array human STS with concern to impact on 
survival are not reported.  
TGF-β was called the Jekyl and Hyde of cancer [116] for its ability to modulate its 
action from tumor suppressor to tumor promoter. The factors responsible for this transition 
remain unclear. The candidates are both tumor-cell-autonomous TGF-β signaling [117] itself, 
and factors in the tumor microenvironment. Among the latter, inflammatory cells and cancer-
associated fibroblasts [109], as well as angiogenetic factors [117], are considered the most 
potent modulators of TGF-β action.  
 
1.2.4.2.  NF-κB 
NF-κB is a protein complex that controls the transcription of DNA. There are five 
proteins in the mammalian NF-κB family which share structural homology with the 
retroviral oncoprotein v-Rel, and therefore frequently classified as NF-κB/Rel proteins. These 
are transcription proteins responsible for control of inflammation, regulation of cell cycle and 




NF-kB is constitutively activated in various tumor cells where it promotes cell 
proliferation, survival, metastasis, inflammation, invasion, and angiogenesis [118]. Its 
influence on tumorigenesis is rather controversial. Indeed, while the majority of the 
investigators confirm that this marker augments tumor invasiveness and metastasis resulting 
in shorter DSS, in a recent study NF-kB p 105 was reported to have a favourable impact on 
DSS in operable non-small cell lung carcinoma patients [119]. 
In STS, NF-kB has also been shown to be both a progenitor [120,121] and inhibitor 
[122] of tumor growth and proliferation. However, all these studies were based on sarcoma 
cell lines in vitro or animal models. NF-kB expression patterns in native human STS and, 
more specifically, its impact on survival is not investigated. 
 
1.2.4.3.  Regulators of motility and adhesiveness 
The process of malignant transformation in epithelial cell is usually characterized by 
loss of adhesiveness and gain of motility. Fascin and E-cadherin have inverse effects related 
to cell motility and cell adhesiveness and important factors in the progression and metastasis 
of cancers [123].  
Fascin is an actin-binding protein that is normally found in membrane ruffles, 
microspikes, and stress fibers at the leading edges and borders of mesenchymal, nervous 
and endothelial cells. It has a key function in forming the parallel actin bundles that hold 
lamellipodial and filopodial cell protrusions that are main cellular structures for 
environmental guidance and cell migration. In intact cells, the actin-binding function of fascin 
is regulated by to extracellular signals through the activities of PKCα and small GTPases. 
[124,125]. Fascin has been reported to be overexpressed in sarcomatoid in contrast to 
conventional non-small cell lung carcinoma [126]. In leiomyomatous tumors of the uterus it 
was associated with higher malignancy grade [127].  
E-cadherin is responsible for epithelial cell junction/adhesion. It is rarely expressed in 
STS, except for synovial and epithelioid sarcomas, as well as mesothelioma, which naturally 





1.2.4.4.  Regulators of cell polarity 
Almost all cell types exhibit some sort of polarity, which enables them to carry out 
specialized functions. Par-6 and PKC-ζ (one of four atypical PKCs) belong to the Par3/Par-
6/aPKC polarity complex that governs diverse cell functions such as localization of 
embryonic determinants and establishment of tissue and organ during the embryonal period. 
In mature organisms, they are responsible for regulation of cell polarity and the asymmetric 
division of cells [128]. Both Par-6 and PKC-ζ have been identified as EMT-associated 
biomarkers [129] and found to enhance proliferation, migration and invasiveness in cell 
cultures [130,131]. In one rare study on PKC-ζ in real human tumors, Cornford et al. reported 
that PKC-ζ expression was significantly higher in prostatic carcinomas than in non-neoplastic 
prostate tissue [132]. In addition, it was shown to have a crucial role at a post-viral entry stage 
of HHV-8 infection in Kaposi sarcoma [133]. The patterns of Par-6 and PKC-ζ expression 
and their possible prognostic impact have not been investigated in sarcomas. 
 
1.2.4.5.  Female steroid hormone receptors 
Estrogen receptors (ER) are a group of mostly intranuclear receptors activated by the 
hormone 17β-estradiol (estrogen). There are two separate, but highly homologous isoforms of 
ER, ERα and ERβ, which have completely different tissue distribution [134]. They are 
encoded by two separate genes, ESR1 and ESR2, respectively. ER, mostly in α isoform, 
mediates the action of estrogens and is responsible for growth and differentiation of target 
cells.  
Like ER, PgR protein exists as two receptor isoforms (PgR-A and PgR-B), but these 
are product of the same gene. PgR is considered the ER’s antagonist. However, selective 
ablation of PgR-A in a mouse model, resulted in exclusive production of PgR-B indicating 
that PgR-B contributes to, rather than inhibits, epithelial cell proliferation both in response to 
estrogen alone and in the presence of progesterone [135]. 
These steroid hormone receptors act as ligand-activated transcription factors. There 
exist several mechanisms with such action, including (1) classic, when transcription starts 
after receptor-ligand complex binding to the specific response element in the gene promoter, 
(2) response element – independent pathway via binding to a transcription factor which in 
turn directly contacts the target gene promoter, (3) ligand – independent genomic action, 




binding to the specific response element in the gene promoter and 
transcription/translation/protein synthesis, and (4) non-genomic actions, involving 
extranuclear fraction of hormone receptors [136].  
Both ER and, to a lesser degree, PgR are well known predictive markers of endocrine 
therapy in breast cancer [137,138]. They are also shown to have a slight positive prognostic 
effect irrelative of endocrine therapy [103]. Steroid hormone receptors are known to be 
expressed in some extent by soft tissue tumors. In leiomyomatous tumors of the uterus, their 
expression level correlates inversely with tumor malignancy grade [139,140]. In addition, it 
was shown effect of hormone-ablation therapy in aggressive intraabdominal fibromatosis 
[141]. 
 
1.2.4.6.  PI3K-Akt signaling pathway 
The main actors in the PI3K/Akt pathway are PI3K and Akt, performing similar 
functions, as well as their inhibitor PTEN (phosphatase and tensin homolog deleted on 
chromosome 10), which is a lipid phosphatase that removes the phosphate group from the 3' 
position of the inositol ring of PIP3, thereby blocking Akt activation. Akt is a serine/threonine 
protein kinase that exists in three highly homologous isoforms, including Akt1, Akt2, and 
Akt3.  
Akt can be phosphorylated at threonine 
308
 and at serine 
473
 for Akt1 or homologous 
sites for Akt2 and Akt3 by, correspondingly, mTORC2 and PDK2 belonging to the 
phosphoinositide 3-kinase (PI3K)/Akt pathway. Activated Akt can activate or deactivate its 
multiple substrates, including mammalian target of rapamycin (mTOR), bcl-2 family member 
BAD, transcription factor forkhead homolog 1 in rhabdomyosarcoma (FKHR), Mdm2 
protein, glycogen synthase kinase 3 (GSK3) and many others, via its kinase activity 
[142,143]. The PI3K/Akt pathway has been linked to an extraordinarily diverse group of 
cellular functions, including cell growth, proliferation, differentiation, motility, survival and 
intracellular trafficking and angiogenesis [144]. Both PI3K and Akt isoforms have been 
implicated as major players in many types of cancer [145-147]. 
The PI3K/Akt pathway seems to be more often deregulated in cancer than any other 
pathway [148]. However, in the literature there is disagreement regarding the prognostic 
impact of Akt expression. While the majority of studies agree that Akt expression overtly 




[152,153]. Expressions of PI3K/Akt pathway components have rarely been investigated in 
STSs and there are almost no studies devoted to their prognostic value [154].  
Different physiological functions of the Akt family kinases imply that the expression 
of its isoforms may also have different prognostic impact in cancer. The significance of this 
variation for the survival of the STS patients is not well investigated and it is not clear 
whether the site of phosphorylation and the pattern of expression play prognostic roles. 
 
1.2.4.7.  Crosstalk among intracellular pathways responsible for tumor growth, 
proliferation and differentiation 
The interplay between pathways responsible for tumor growth, proliferation and 
differentiation is tightly regulated both spatially and temporally. This gives rise to the 
remarkable complexity, diversity, and flexibility of the ways the cell function can be 
performed in order to augment proliferation and (de)differentiation. This has been 
exemplified by a great number of studies. 
The PI3K/Akt action is documented to enhance TGF-β-induced apoptosis and/or cell 
cycle arrest in multiple types of cells in response to several activating agents [155,156]. Akt 
activity, in turn, is also shown to increase in response to TGF-β treatment. It seems to be 
required for several of TGF-β - induced activities, such as cell migration of HER2-expressing 
breast cancer cells [157], and EMT of normal mammary epithelial cells [158].  
Both aberrant expression of Smad4 or disruption of Smad4 activity was shown to 
decrease the TGF-beta suppression of ER-alpha transactivity in breast cancer cells [159]. The 
investigation of EMT revealed synergistic roles for TGF-β/BMP signaling pathway 
components, fascin, NF-κB, Par-6 and PKC-ζ in forming of motile phenotype in cancer cells 
[160-163]. 
Female steroid hormone receptors, as it was mentioned earlier, act as growth factors 
[164] and can be activated in a ligand – independent genomic way. It has been described 
reciprocal mutual activation of elements of PI3K-Akt pathway and ER [165]. Steroid 
hormone receptors are also the targets of protein kinase A, MAPK, CDKs, casein kinase, and 
GCK3 [166,167] in this context. Finally, NF-kappaB activation can influence ER recruitment 





1.3.   Tissue microarray 
 Tissue microarrays (TMAs) represent an powerful technology tool designed to explore 
molecular targets, on DNA, RNA or protein level, from several tissue specimens assembled in 
a single microscope slide[169]. This method implies the extraction of small tissue cylinders 
from donor tissue block to be embedded in a recipient block (Figure 7).  
 
Figure 7: Tissue microarray method. Cores punched from the donor blocks and embedded into the 
recipient block. The TMA block can then be sectioned and used for various staining methods. Adapted 
from Chen W, Foran DJ: Advances in cancer tissue microarray technology: Towards 
improved understanding and diagnostics. Anal Chim Acta 2006 [170] Permission obtained from 
Elseiver Inc. 
 
This block can then be cut into thin slices available for immunohistochemistry (IHC), 
in situ hybridization etc. Once constructed, one block could potentially yield tissue to several 




The method was first introduced by Battifora 1986 as so called “multitumor (sausage) 
tissue block"[173] and further modified in 1990 with its improvement, "the checkerboard 
tissue block”[174]. Although offering significant benefits even at this early stage, the TMA 
technique was not embraced on a large scale before Kononen et al. devised an instrument able 
to standardize the TMA construction process in 1998 [175]. Adaptation has also allowed the 
use of other than paraffinized tissues, including frozen tissue, cell-lines and needle biopsies. 
This has led to an vast increase of TMA studies and in 2007 nearly 10% of all biomarker 





2. AIMS OF THESIS 
 The presented thesis was aimed at exploring potential prognostic markers of tumor 
growth, proliferation and (de)differentiation for non-GIST STSs. 
 
More specifically the aims were to: 
 
 Elucidate the prognostic significance of dedifferentiation-related factors in 
tumor cells of non-GIST STSs. 
 
 Investigate the distribution and prognostic impact of ER and PgR in tumor 
cells of non-GIST STSs.  
 
 Evaluate the prognostic impact of the proteins belonging to PI3K-Akt 






3. MATERIAL AND METHODS 
3.1.  Study population and material 
Figure 8 shows the inclusion and exclusion of patients in the different studies. A 
retrospective archival search for sarcoma diagnosis was done at the University Hospital of 
North-Norway (1973 – 2006) and the Hospitals of Arkhangelsk County, Russia (1993 – 
2004). Regarding the Russian material, there was asked for material from a ten year period 
due to the fact that the archival system before the chosen time frame was less organized. A 
total of 959 patients were found (Norwegian, n = 632; Russian, n = 337).  
Formalin-fixed and paraffin-embedded specimens from primary tumor tissue were 
obtained and all biopsies were reevaluated by two experienced pathologists. The tumors were 
graded according to the FNCLCC system and histologically subtyped according to the World 
Health Organization guidelines. For the Russian material there were made new slides of all 
the paraffin blocks. For the Norwegian material new slides were made when necessary. All 
the biopsies were immunostained with CK, CD117, actin, SMA, vimentin and CD34. Some 
slides were also stained with S100 when necessary to rule out or confirm a differential 
diagnosis. Other molecular methods were not considered as necessary for differential 
diagnostics, but in some cases PCR or FISH were performed in the initial diagnostics. About 
10 % of the initial diagnoses were revised due to changing classification systems and 
appearance of new entities such as GIST. Non-sarcomas, other sarcomas not classified as STS 
as well as GISTs were excluded: carsinosarcomas (n= 81), dermatofibrosarcoma protuberans 
(n= 78), GISTS (n = 47), osteosarcomas (n=42), chondrosarcomas (n = 30), Kaposi sarcomas 
(n=30), endometrial stromal tumors (n=27), benign tumors (n=18), malign mesotheliom (n 
=11) and other sarcomas/unknown (n=99).   
A total of 496 non-GIST STSs (Norwegian, n = 299; Russian, n = 197) were 
registered. However, 247 patients were excluded due to missing clinical data (n = 86) or 
inadequate paraffin embedded fixed tissue blocks (n = 161). Thus 249 non-GIST STSs 






Figure 8: Flow-chart visualizing inclusion and exclusion of patients in the study. 
 
Demographic and clinical data were collected retrospectively and include follow-up 
data as of September 2009. The minimum follow up for the survivors was 41 months and the 
median follow-up for the entire patient population was 37.6 (range 0.1-391.7) months.  
 
3.2.  Immunohistochemistry (IHC) 
3.2.1.   IHC procedure 
 The applied antibodies were subjected to in-house validation by the manufacturer for 
IHC analysis on paraffin-embedded material. The antibodies used in the study are 
summarized in Table 4.  
 Four µm thick sections were deparaffinized with xylene and rehydrated with ethanol. 
Antigen retrieval was performed exposing slides to microwave heating for 10×2 min at 450 W 





, Akt2, Akt3, PI3K and PTEN. For steroid hormone receptors, TGF-β1, PKC-ζ, Par-
6α, E-cadherin and vimentin, Ventana Antigen Retrieval Cell Conditioning Buffer 1 




for PgR, TGF-β1, PKC-ζ, Par-6α, E-cadherin, and standard regimen (64 min) for ER and 
vimentin. TGF-β1, PKC-ζ, Par-6α, E-cadherin, vimentin, ER and PgR were stained using 
Ventana Benchmark XT (Ventana Medical Systems Inc), procedure iViewDAB.  
Primary antibodies against PgR, TGF- β 1, PKC-ζ, E-cadherin, ER and Par-6α were 
incubated at 37°C for 24, 28, 28, 32, 32 and 52 min, accordingly. Primary antibodies against 




, Akt2, Akt3 and PTEN were 
incubated overnight at 4°C, while those against fascin and PI3K were incubated 
correspondingly for 30 and 32 minutes at room temperature. 
The DAKO EnVision + System-HRP (DAB) kit was used as endogen peroxidase 
blocking agent and to visualize the antigens for all stains. This yielded a brown reaction 
product at the site of the target antigen. As negative staining controls, the primary antibodies 
were replaced with the primary antibody diluents. All slides were counterstained with 
hematoxylin to visualize the nuclei. For each antibody, including negative controls, all TMA 
staining were performed in one single experiment. 
 
Table 4. Schematic overview of the antibodies used in the studies. 
Antigen Dilution Antibody Clone Source 
TGF-β1 1:50 Rabbit polyclonal SC-146 Santa Cruz Biotechnology  
Fascin 1:25 Mouse monoclonal MAB3582 Chemicon International 
NF-κB p105 1:50 Rabbit monoclonal 4808 Cell Signaling Technology 
PKC-ζ 1:100 Rabbit polyclonal SC-216 Santa Cruz Biotechnology  
Par-6α 1:10 Rabbit polyclonal SC-25525 Santa Cruz Biotechnology  
E-cadherin Prediluted Mouse monoclonal ECH-6 Cell Marque 
Vimentin Prediluted Mouse monoclonal V9 Ventana Medical Systems 
ERα Prediluted Mouse monoclonal SP1 Ventana Medical Systems 
PGR Prediluted Mouse monoclonal 1E2 Ventana Medical Systems 
phosphoAkt Thr
308
 1:50 Rabbit monoclonal 244F9 Cell Signalling Technology 
phosphoAkt Ser
473
 1:5 Rabbit monoclonal 736E11 Cell Signalling Technology 
Akt2 1:18 Rabbit monoclonal 54G8 Cell Signalling Technology 
Akt3 1:8 Rabbit monoclonal 4057 Cell Signalling Technology 
PTEN 1:10 Rabbit monoclonal 9559 Cell Signalling Technology 





3.2.2.   Scoring 
The ARIOL imaging system (Genetix, San Jose, CA) was used to scan the slides of 
antibody staining of the TMAs. The slides were loaded in the automated slide loader (Applied 
Imaging SL 50) and the specimens were scanned at low resolution (1.25×) and high resolution 
(20×) using the Olympus BX 61 microscope with an automated platform (Prior). 
Representative and viable tissue sections were scored manually on computer screen semi 
quantitatively for cytoplasmic staining. The dominant staining intensity was scored as: 0 = 
negative; 1 = weak; 2 = intermediate; 3 = strong. All samples were anonymized and 
independently scored by two trained pathologists. When assessing a variable for a given core, 
the observers were blinded to the scores of the other variables and to outcome. All cores from 
each patient were scored by the two pathologists. Mean score from each individual was 
calculated separately. Cut-off values with regard to high and low expression were decided as 
described in chapter 5.1.4.2. For E-cadherin, NF-κB, PKC-ζ, ER and PgR the cut-off points 
were established at 0. For other markers, high expression of tumor cells were defined as ≥ 0.5 
(PI3K and PTEN), ≥ 1.0 (phosphoAkt Ser
473
) and ≥ 2 (TGF-β1, fascin, Par6, vimentin, 
phosphoAkt Thr
308
, Akt2 and Akt3). 
 
3.3.  Statistical analysis 
All statistical analyses were done using the statistical package SPSS (Chicago, IL), 
version 16. The IHC scores from each observer were compared for interobserver reliability by use 
of a two-way random effect model with absolute agreement definition. The intraclass correlation 
coefficient (reliability coefficient) was obtained from these results. The Chi-square test and 
Fishers Exact test were used to examine the association between molecular marker expression and 
various clinicopathological parameters. Univariate analyses were done using the Kaplan-Meier 
method, and statistical significance between survival curves was assessed by the log rank test. 
DSS was determined from the date of diagnosis to the time of cancer related death. To assess the 
independent value of different pretreatment variables on survival, in the presence of other 
variables, multivariate analyses were carried out using the Cox proportional hazards model. Only 
variables of significant value from the univariate analyses were entered into the Cox regression 
analyses. Probability for stepwise entry and removal was set at .05 and .10, respectively. The 
significance level used for all statistical tests was P < 0.05, but in the subgroup analysis the 





3.4.  Ethical clearance  
The National Data Inspection Board and The Regional Committee for Research Ethics 





4. MAIN RESULTS 
4.1.   Paper I  
 This study was designed to investigate the prognostic impact of the dedifferentiation-
associated biomarker expression in tumors from patients with non-GIST STS. These markers 
were shown to induce and/or sustain EMT in epithelial tumors. Interobserver scoring 
agreement was tested for all markers. The intraclass correlation coefficients were 0.92 for E-
cadherin (P<0.001), 0.89 for fascin (P<0.001), 0.91 for NF-κB p105 (P<0.001), 0.86 for Par-
6α (P<0.001), 0.97 for PKC-ζ (P<0.001), 0.87 for TGF-β1 (P<0.001) and 0.93 for vimentin 
(P<0.001). 
 In univariate analyses of the total material TGF-β1 (P=0.016), fascin (P=0.006), NF-
kB p105 (P=0.022) and PKC-ζ (P=0.042) were significant indicators of shorter DSS, while in 
subgroup analysis, high TGF-β1 expression was a negative prognostic indicator particularly 
for undifferentiated pleomorphic sarcoma (P<0.001) and for trunk-located STS (P=0.003). In 
the multivariate analysis, high TGF-β1 expression was an independent negative prognostic 
factor for DSS (HR=1.6, 95% CI=1.1-2.4, P=0.019) in addition to tumor depth, malignancy 
grade, metastasis at diagnosis, surgery and positive resection margins in the total patient 
cohort.  
 
4.2.   Paper II  
 The estrogen (ER) and progesterone receptor (PgR) regulate growth and cell 
differentiation upon ligand-dependent and ligand-independent activation. In breast cancer and 
gynecological tumors their expression are known predictors of endocrine therapy benefits and 
a favorable therapy-independent prognosis. The study aimed to investigate the distribution 
and possible prognostic impact of ER and PgR expression in non-gastrointestinal stromal 
tumor soft tissue sarcomas (non-GIST STSs). Interobserver scoring agreement was tested for 
both steroid hormone receptors. The intraclass correlation coefficients were 0.92 for ER 
(P<0.001) and 0.96 for PgR (P<0.001). 
 Uterine leiomyosarcomas expressed ER and PgR most frequently and intensively. 
However, the moderately and especially weakly positive tumors were distributed relatively 
equally between genders and histological entities. The expressions of ER and PgR correlated 
strongly with each other (r=0.206, P=0.002). Fifty-three percent of STSs expressed at least 




Neither ER nor PgR showed significant prognostic impacts on DSS by analysing the 
whole cohort. Though, separate analyses of each gender revealed that ER expression was a 
significant positive prognostic factor in women (P=0.017), while PgR expression was 
associated with a poor prognosis in men (P=0.001). Among the four possible co-expression 
patterns of ER and PgR, the ER-/PgR+ profile for the whole cohort, which was seen in 14% 
of the patients (n=34), was associated with a miserable prognosis (P<0.001). In the 
multivariate analysis, this ER-/PgR+ phenotype was an independent negative prognostic 
factor for DSS (HR=1.9, 95% CI=1.2-3.1, P=0.008) in the total patient cohort. 
 
4.3.   Paper III  
 The PI3K/Akt pathway is involved in cellular survival pathways by inhibiting 
apoptotic processes and stimulating cell growth and proliferation. Its negative prognostic 
value has been proven in many types of cancer. The aim of this study was  to investigate the 




, Akt2, Akt3, 
PI3K and PTEN, alone and in coexpression with ER and PgR in non-gastrointestinal stromal 
tumor soft tissue sarcomas (non-GIST STSs). Interobserver scoring agreement was tested for 
all markers. The intraclass correlation coefficients were as follows: 0.89 for p-Akt Ser
473
 
(P<0.001), 0.94 for p-Akt Thr
308
 (P<0.001), 0.91 for Akt2 (P<0.001), 0.95 for Akt3 
(P<0.001), 0.88 for PI3-K (P<0.001) and 0.89 for PTEN (P<0.001). 
 In univariate analyses of the total material, p-Akt Thr
308
 (P=0.002), Akt2 (P=0.008) 
and PI3K (P<0.001) were significant indicators of shorter DSS. Nuclear expression of p-Akt 
Thr
308 
expression showed a significantly favorable prognosis (P=0.029), compared to 
cytoplasmic and especially mixed cytoplasmic and nuclear expression.  
Subgroup analysis based on patients’ gender revealed that high expression of p-Akt 
Thr
308 
was a negative prognostic factor particularly for men (P=0.009 vs. P=0.064 for 
women). In contrast, p-Akt Ser
473
 appeared to be a negative prognosticator exclusively for 
female patients (P=0.023 vs. P=0.87 for men). Expression of steroid hormone receptors also 
showed opposite prognostic impacts depending on patient’s gender. This was further proved 
by the co-expression of these factors. Among others, PgR-/p-Akt Ser
473
+ phenotype tended to 
have an unfavorable impact in women (P=0.087) but was clearly favorable in men (P= 0.010).  
In the multivariate analysis of the total material, PI3K expression by tumor cells 






5.1.   Methods 
5.1.1.   Data collection and study population 
As in many similar studies, the representativity of the studied population is a major 
issue. We have included patients from two countries, Norway and Russia, to achieve more 
statistical power for the statistical analyses. On the other hand, the possibility of population 
heterogeneity can be a potential drawback. However, the populations are both ethnically and 
geographically close as illustrated by a similar distribution of clinopathological variables. 
Despite possible differences with respect to diagnoses or treatment traditions, the revision of 
all tumors and the relatively limited and grossly comparable choice of curative strategies 
made it meaningful to study both the Norwegian and Russian patients in one cohort. Besides, 
the study focuses on the natural biology of the STSs and not on the treatment modalities. 
 
5.1.1.1.  Representativity of Norwegian and Russian study populations 
In 23 years (1973-2006), the estimated number of STSs in Northern Norway is about 
230-460 STS patients, taking into consideration the total incidence (of about 0.5 – 1% of all 
cancers annually) and the proportion of the population living in Northern Norway, comprising 
approximately 10%. There were 299 Norwegian non-GIST STSs observed in our population 
before excluding 132 cases due to missing clinical data or inadequate paraffin-embedded 
fixed tissue blocks (Figure 8). Since missing cases are at random, it can be argued that the 
patient population is not selection biased and therefore representative.  
Though the Norwegian material is representative, one may to a larger degree question 
the representativity of the Russian material. The population of Arkhangelsk Oblast is about 
three times larger than Northern Norway. As the number of Russian population in our study 
(n=82) is about one third of the Norwegian material, there should definitely be more patients 
in the Russian material, although the time of the material collection here (1993-2004, 11 
years) comprised one third (1973-2006, 33 years) of the Norwegian inclusion period. 
However, the number of Russian patients in our studies is about one third of the Norwegian 
study population. This potential selection bias should be taken into account when our results 
are being analyzed. We also see that subgroups of the Russian patients have significantly 




clinicopathological variables, only the distribution of malignancy grade is significantly altered 
in the Russian versus the Norwegian material. The increased number of Russian patients with 
malignancy grade 3 may explain at least some of the reduced survival rate in the Russian 
population. This in turn can be explained by the fact that a considerable part of the Russian 
material was from the Arkhangelsk Regional Oncology Center, while a proportion of patients 
with less malignant tumors could potentially be cured locally at the local district hospitals. 
Hence, a selection bias of the Russian material can not be ruled out.  
 
5.1.1.2.  Patients without metastasis at the time of diagnosis and non-operated patients 
Many translational studies conducted on sarcomas exclude high-risk categories of 
patients, namely those with inoperable status and metastasis at the time of diagnosis, from 
study population in terms to achieve more homogeneity. Ideally, one should analyze these 
groups separately, to avoid a probability of removing potential prognostic significance of 
individual markers, i.e. increased chance of false negative results. 
We have repeated all statistical analyses based on patients who did not undergo 
surgery and did not have metastasis at the time of diagnosis. The exclusion reduced the total 
number of non-GIST STS patients from 249 to 194. Analyses have been done in these 
patients as a total group (n = 194) and (for article 2 and 3) separately for men and women. 
Paper I 
Among the markers we investigated in the first study, again TGF-β1 (P=0.035) and 
fascin (P=0.010) were significant indicators of shorter DSS, NF-kB p105 (P=0.050) was 
borderline significant, while PKC-ζ showed a tendency towards significance (P=0.096). In the 
Cox analysis, TGF-β1 tended to a significant value (P=0.075).  
Paper II 
For paper II, neither ER nor PgR expressions were significant in total group patients, 
but as in the published analysis PgR was a negative prognosticator in men (P=0.010) and ER 
a significantly favorable prognostic factor for women (P=0.041). ER-/PgR+ phenotype was an 
independent negative prognosticator in all patients (HR=2.8, 95% CI=1.4-5.6, P=0.007) and 
in the subgroup of women (HR=2.0, 95% CI=1.0-4.0, P=0.036).  
Paper III 
And finally, the PI3-Akt signalling proteins showed the same poor prognostic 
significance as in the original paper in univariate analyses of p-Akt Thr
308
 (P=0.045), Akt2 




analysis. Nevertheless, after the excluding tumor grade from the multivariate analysis, PI3K 
appeared as an independent negative prognostic factor (HR=1.6, 95% CI=1.1-2.5, P=0.027). 
 
5.1.1.3.  Patients without gender-associated sarcomas 
As our results may potentially be distorted by the inclusion of gender-related sarcomas 
in our study, we excluded gender-related sarcomas (44 leiomyosarcomas located in uterus) 
from our database and carried out both univariate and multivariate analyses for whole cohort 
and, for ER, PgR and PI3K-Akt signalling system proteins, separately for each gender.  
In the dedifferentiation-related group of proteins, the results of this rescoring were 
generally unaltered with only minor changes in P values: TGF-β1 (P=0.047), fascin 
(P=0.013), NF-kB p105 (P=0.043) and PKC-ζ (P=0.001) were significant indicators of shorter 
DSS, while only TGF-β1 was significant in the multivariate analysis (HR=1.5, 95% CI=1.0-
2.3, P=0.035). ER and PgR also showed comparable values, with the ER-/PgR+ phenotype as 
an independent negative prognosticator (HR=1.8, 95% CI=1.1-2.9, P=0.025) for the total 
patient cohort.  
With respect to the PI3K-Akt signalling system, results corresponded to those obtained 
without exclusion of gender associated sarcomas, except for Akt3 evaluated in the total 
cohort. Unlike in previous calculation, Akt3 showed a significantly negative impact in the 
univariate analysis (P=0.042). PI3K alone was an independent negative prognosticator of 
survival among the investigated markers, though both significance and the hazard ratio were 
higher compared results including gender-related sarcomas (HR=1.9, 95% CI=1.2-2.9, 
P=0.005 versus HR=1.5, 95% CI=1.0-2.2, P=0.042).  
In conclusion, the inclusion of gender-related sarcomas did not appear to alter our 
results.  
 
5.1.1.4.  Separate investigation of differently located sarcomas 
Based on clinical and prognostic data, sarcomas located on extremities and trunk (ET), 
versus retroperitoneal and visceral tumors (VR) may be regarded as distinct STS entities. In 
the ET group, metastases are the main cause of sarcoma-related death, while local relapse is a 
more common cause of sarcoma-death in STSs in the VR group. We have stratified patients 
according to ET (n=115) versus VR (n=66) subgroups (patients with head and neck STSs 




original papers were persistent in the ET sarcomas. For the VR group, the number of 
patients was insufficient for reliable analyses.  
 
5.1.1.5.  Heterogeneity of histological entities in study population 
Another major issue is the heterogeneity with regard to the histological entities 
included in the analyses. This introduces the possibility that expression of the prognostic 
molecules investigated could be differently expressed in some subgroups. We conducted 
subgroup analyses of the histological entities concerning the expression of investigated 
molecules, and found the same tendencies in the larger subgroups when compared to the 
smaller subgroups.  
 
5.1.1.6.  Conclusion on material representativity 
In conclusion, the data collection introduced problems in identifying adequate 
numbers of similar patients with similar tumors and with the same treatment traditions. These 
are all known problems when conducting STS studies. Our findings are in large hypothesis 
generating, and to be more conclusive future STS studies must be based on large, multi-
institutional and multinational studies with possibilities to establish large enough patients STS 
cohorts of more homogenous tumor groups. However, all the tumors we investigated had 
mesenchymal derivation and belong to the same generic group. Moreover, the investigated 
dedifferentiation and proliferation markers probably to a large degree reflect universal and 
basic processes in tumorigenesis. They are described in a variety of epithelial and non-
epithelial tumors of different locations and histological entities and seem not to depend on 
tumor type. 
 
5.1.2.   Tissue microarray 
 Among the obvious advantages of the TMA technique compared to whole slide 
assessments are the high throughput, cost benefit, possibility for large cohorts simultaneously, 
supreme staining standardization, reproducibility as well as relative simplicity. It is also 
possible to use the donor specimens for further analysis and share the material between 
different institutions.  
Along with these apparent benefits, there are some drawbacks often discussed with 




TMA analysis give meaningful information on large tumor specimens. Instead of 0.6 mm 
cores, some investigators have used larger cores (2-4 mm or more) to increase the 
representativity [176-178]. Others suggest that punching multiple small cores from different 
regions better captures the heterogeneity of the tumors [169]. We chose using duplicate 0.6 
mm cores which were selected to be as representative as possible, after reviewing all the 
original sections of the tumor and taking heterogeneity into consideration. Up to 95% 
correlation has been demonstrated when comparing tumour cell assessment in duplicate 0.6 
mm cores versus the whole slide [169].  
Another often mentioned drawback is that TMAs are not suitable to individual 
diagnosis of patients. In the involved institutions, all diagnostic procedures were performed 
using full slides, before construction of TMAs for marker studies. 
 
5.1.3.   Immunohistochemistry 
IHC is only one of many techniques used to analyze tissues for expression of proteins 
and other molecules. More advanced techniques are available. Nevertheless, IHC continues to 
prove its worth. It is reliable, well developed and known, easy to interpret, widely available 
and routinely used in pathological laboratories. Unlike modern array techniques, IHC 
visualizes the final protein product, localization of the protein and not merely an up or down 
regulated gene etc.  
 
5.1.3.1.  Antibodies 
Choosing antibodies is one of the major steps in conducting an IHC study. When 
available, commercial antibodies are the best choice, as they have data leaflets with rigorous 
specifications and are easily available for conformational studies. The next step is choosing 
between monoclonal and polyclonal antibodies. Monoclonal antibodies are all targeting one 
epitope on the antigen providing excellent specificities. In addition, they are homogenous 
from production lot to production lot, making conformational studies easier to conduct. The 
drawback of monoclonal antibodies is the chance that post processing of the tissue could lead 
to concealment of the targeted epitope and a type II error. Polyclonal antibodies target several 
epitopes on the same antigen resulting in a more robust antigen binding. The robust antigen 
binding happens at the cost of a risk of cross reaction with other antigens and an increased 




The Sarcoma Study Group is a part of a larger Translational Cancer Research Group. 
All the immunomarkers we used were chosen from published literature and validated by both 
manufacturer and previous studies of lung cancer in our research group [119,179]. 
A common concern is whether improper tissue storage over years may affect the IHC 
results. To address this question we have divided the total material (n = 194) based on date of 
diagnosis, both in three categories (1973-1989, n = 48; 1990-1999, n = 97 and 2000-2006, n = 
49) and in two categories (1973-1996, n = 101 and 1997-2006, n = 93). There were no 
significant differences (defined as r > 0.2, P < 0.01 due to multiple testing) in any of the 
marker expressions with regard to time-period.  
 
5.1.3.2.  Controls 
Antibody specificity is ensured by a western blot showing binding of a protein of the 
expected size. In the case of the antibodies used in our studies, this was done by the 
manufacturer and presented in the data leaflets of the antibodies. 
Positive and negative controls are normally conducted to control the quality of IHC 
experiments. Negative controls are conducted by replacing the primary antibody with a 
primary antibody diluent, to check for unspecific staining in the absence of the antibody. 
Negative controls could be made even more stringent by introducing isotype controls to check 
for unspecific binding. In addition, there were tissue controls with other tumor groups and 
normal tissue on each TMA slide, representing both positive and negative controls.  
 
5.1.4.   Statistics 
There are almost as many approaches to statistical analysis of survival data as there are 
studies on survival and no optimal method of analysis exist. In order not to over- or under-
interpret the significance of their data, investigators have to be vigilant in their choosing of 
different analyses. We believe that we in our analyses have found a reasonable balance 
between type I and type II errors. A short discussion of the statistical methods used in our 
studies is presented below. 
 
5.1.4.1.  Significance level 
Type I errors occur when inappropriate significance levels are used. In biological 




considered significant. This gives that one in twenty tests for the same difference will be a 
type I error. When conducting a large number of tests the chance of an erroneous positive 
result thus increases. There have been developed several approaches for reducing the chance 
of type I error in the setting of multiple testing. The drawbacks of these are the increased 
chance of type II error. There is no consensus whether such methods should be used in 
prognostic studies. We chose not to conduct a correction of multiple testing as we see our 
studies as hypothesis generating. This gives us an increased risk of type I errors, but decreases 
the chance of type II errors. 
 
5.1.4.2.  Cut-off values 
In prognostic biological studies the cut-off values are meant to divide the subjects 
under investigation into diagnostic groups based on the relative expression of proteins, 
mRNA etc. As biological values are continuous scales this gives a skewed view on reality and 
the results must be interpreted in that context. The most common approach is to dichotomize 
the material, but sometimes several groups give a better picture. When choosing the cut-off 
values the researchers must choose between using a predefined value either based on previous 
research, the mean or median, percentiles, standard deviations etc. or finding the cut-off value 
that yields the two groups with the largest possible difference in the end-point under 
investigation. There are drawbacks and advantages to both approaches. When using a 
predefined cut-off value the chances of type I errors decreases at the cost of type II errors. In 
many cases it is also difficult to find meaningful previous studies suggestive of a usable cut-
off value. In the case of a conformational study, using a predefined value makes sense since 
there already is established a cut-off. In the case of a novel study, choosing the mean, median 
or percentiles as cut-off values makes sense in that it increases the reproducibility of the cut-
offs and therefore will be easier to evaluate in a conformational study. When choosing the 
cut-off that yields the two groups with the largest possible difference in prognosis, the 
chances of type II errors decreases at the cost of type I errors. This approach makes sense in 
novel hypothesis generating studies where there are no predefined values to help choose the 
appropriate cut-offs. Such studies could be the basis of further research into novel fields and 
their results should be interpreted in this light. We have used the latter approach in our studies 
and we regard our findings as hypothesis generating. Hence, our results should be confirmed 





5.1.4.3.  Survival analysis 
There are several ways in which survival data can be analyzed and interpreted. One 
well proven method is the Kaplan-Meier (KM) analysis which tests the difference between 
groups in time to event data. However, the KM method does not adjust for the presence of 
other clinical variables. To address this point we used the Cox-proportional hazards method to 
adjust for clinical variables found to be significant using the KM method. This stringent 
method works to ensure that the variables found in our studies are in fact independent of 
known demographic, clinical or pathological variables and could therefore contribute when 
calculating the prognosis of non-GIST STS patients.  
An issue is which endpoint to use. In prognostic studies there is a variety of endpoints 
as overall survival (OS), metastasis free survival (MFS), time to recurrence (TTR), time to 
progression (TTP)  and as we have chosen, DSS. DSS is a well-established endpoint and, in 
this case, excludes patients with non-sarcoma related deaths.  
 
5.2.   Discussion of results 
Sarcomas are rare tumors, and large cohorts of patients are therefore relatively rare in 
studies on non-GIST STS. Our study population is quite large compared to similar studies. 
Fully reassessed histology, scrutinized staining, visualizing and scoring processes, as well as 
comprehensive clinical data for each patient and rather long follow-up provides objectivity to 
the study performance and assessment. This was further augmented by the possibility to 
investigate the prognostic impact of several families of proteins which are responsible not 
only for tumor growth, proliferation and differentiation, but also for angiogenesis and local 
immunity, and estimate possible co-expressions within and between these marker families.
 Although the total amount of patients in our studies is rather large, the histological 
subgroups are not numerous enough to conduct meaningful subgroup analyses, which is 
common problem in sarcoma-related research. Among other possible concerns are differences 
in treatment over time and between Norwegian and Russian patients and challenges regarding 
IHC. Nevertheless, the results of the univariate and multivariate analyses of the 
clinicopathological variables in the present cohort are in accordance with the published 
literature indicating a representative patient population and a good basis for marker analyses. 





In summary, the results of our studies presented herein suggest the involvement of 
these markers in tumor growth, proliferation and (de)differentiation in development, behavior 
and, finally, prognosis of non-GIST STS. The exact mechanisms of such involvement are, 
however, yet to be elucidated. 
 
5.2.1.   Paper I 
In this study we investigated the prognostic impact of a set of biomarkers in non-GIST 
STS patients known to participate in the process of EMT in epithelial tumors [91], but bearing 
other important biological functions as well. TGF-β1, fascin, NF-kB p 105 and PKC-ζ 
showed significant unfavorable influence on survival in the univariate analyses. Besides, high 
expression of TGF-β1 was a significant independent negative prognostic indicator of DSS.  
TGF-β belongs to a TGF-β/BMP family of growth factors and is basically a tumor-
suppressive agent whose functions include proliferation hampering and promotion of 
apoptosis both in normal and tumor cells. There is, however, a broad evidence of its negative 
influence on prognosis, described mostly in epithelial [110,111], but also in mesenchymal 
tumors [112-115]. The possible mechanisms of such pro-neoplastic action include receptor-
inactivating mutations, selective inactivation of the tumor-inhibiting arm of this pathway 
[108], and TGF-β induced systemic immune suppression [109]. Other proposed modulators of 
TGF-β function are factors in the tumor microenvironment, particularly inflammatory cells, 
cancer-associated fibroblasts [109] and angiogenetic factors [117]. We found TGF-β1 to be a 
crucial prognostic marker. It had a significantly independent negative prognostic effect on 
DSS in non-GIST STS.  
Fascin is an actin-bundling protein that is found in membrane ruffles, microspikes, and 
stress fibers [180]. In tumorigenesis, it augments cell motility and is therefore an important 
factor in the progression and metastasis of cancers [123]. Fascin is reported to be 
overexpressed in sarcomatoid, in contrast to conventional, non-small cell lung carcinoma 
[126]. In leiomyomatous tumors of the uterus it was associated with a higher malignancy 
grade [127]. Our data are in accordance with these findings, we found fascin expression to be 
associated with a shorter STS survival in univariate analyses.  
The majority of studies devoted to NF-kB agree that this marker enhances tumor 
invasiveness and metastasis resulting in shorter DSS. This marker is demonstrated  to be 
constitutively activated in various tumor cells where it promotes tumor cell proliferation and 




hand, there are some studies which show tumor inhibiting role of NF-kB. Thus, in a recent 
work by Al-Saad et al., NF-kB p 105 was reported to have a favorable impact on DSS in 
operable non-small cell lung carcinoma patients [119]. We found NF-kB p 105 expression in 
STS to indicate a poor prognosis.  
The polarity complex proteins Par-6 and PKC-ζ have been identified as EMT-
associated factors [129], increasing proliferation, migration and invasiveness in cell cultures 
[130,131]. Cornford et al. reported that PKC-ζ expression was significantly higher in prostatic 
carcinomas than in non-neoplastic prostate tissue [132]. We were unable to find studies on 
Par-6 expression in human sarcomas through PubMed searches. In our study, we observed 
PKC-ζ expression to be a significant indicator of shorter DSS, while Par-6 did not show any 
prognostic significance.  
E-cadherin, being responsible for epithelial cell junction, is rarely expressed in STS, 
except for synovial and epithelioid sarcomas, as well as mesothelioma, which naturally 
express both epithelial and mesenchymal markers. As expected, E-cadherin was in this study 
expressed aberrantly in a minority of STS and failed to demonstrate any association with 
survival. 
Vimentin is a recognized marker of advanced aggressivity in epithelial tumors. Its 
negative influence on patient survival has been demonstrated in several human cancers 
including breast [181], gastric [182] and oral carcinoma [183]. The STSs which by definition 
express vimentin are not generally investigated for the prognostic importance of its grade of 
expression. In our material, all tumor cells were positive for vimentin, but at varying degrees. 
All STSs were dichotomized as strongly positive tumors or not, but there was no difference in 
survival between these two groups.  
The results indicate that the factors known as EMT markers in epithelial malignancies 
have similar roles in the progression of STSs. This, in turn, since STSs are already 
mesenchymal neoplasms, means that EMT, as a term, is either misnomer or just particular 
“epithelial” example of a broader idiom, such as dedifferentiation or anaplasia. 
 
5.2.2.   Paper II 
 In this paper we investigated distribution of female steroid hormone receptors, ER and 
PgR, and found that at least one of them was expressed in 53% of non-GIST STS cases when 
1% is considered a positivity threshold. Further, we found PgR to be a negative prognostic 




prognosticator for female patients. Additionally, we investigated all possible ER/PgR co-
expression profiles and found the ER-/PgR+ phenotype to be an independent negative 
prognostic factor for DSS in the whole cohort of non-GIST STS patients.  
Steroid hormones, and therefore their receptors too, are known to stimulate the 
progression of breast cancer as well as other gynecological tumors. ER served for decades as 
a predictor of success of hormone-ablation therapy for ER-positive in contrast to ER-negative 
breast cancers [137,138]. A diversity of soft tissue tumors expresses both ER and PgR 
[139,184-186], but there is much uncertainty concerning the steroid hormone receptor 
expression value in the mesenchymal tumors. This is probably due to vagueness of positivity 
cut-off for non-gynecological tumors which is as high as 10% in most of studies. We have 
modified the Allred score [187] for STSs and used 1% positivity as cut-off value. The strong 
and moderate (score 3 and 2, respectively) hormone receptor expression occurred mostly in 
sarcomas of uterus, pelvis and breast, while the weak (score 1) expression of both ER and 
PgR was surprisingly evenly distributed among location, gender and age. Generally, 36% of 
the tumors expressed ER and 30% expressed PgR in our material. 
The rate of ER and PgR expression in leiomyomatous tumors of uterus was frequently 
demonstrated to rise with the grade of differentiation of malignant tumors from benign 
leiomyoma to high grade malignant leiomyosarcoma [139,140]. However, the information 
concerning steroid hormone receptor expression in soft tissue tumors outside the 
gynaecological area is scarce and controversial. In our study, ER expression (using positivity 
threshold at 1%) had a positive impact on survival in women (univariate analysis), but failed 
to show any significant value in the Cox proportional hazards analysis. PgR expression 
showed a clearly negative impact on DSS in men and slightly positive, but not significant 
influence on survival in women. 
The value of ER/PgR coexpression profiles is well studied in breast carcinoma. In a 
few words, any hormone receptor positivity gives better prognosis for success of 
antihormonal therapy [188,189]. In our study, the ER-/PgR+ profile (14% of the tumors) was 
a significantly unfavourable factor for the whole patient cohort both in univariate and in 
multivariate analyses.  
This study is, to our knowledge, the first to elucidate the distribution and prognostic 
value of steroid hormone receptors in non-GIST STSs. Both ER and PgR were surprisingly 




Their prognostic significance is not much of a surprise, since both of them in essence are 
growth factors.  
 
5.2.3.   Paper III 
In this paper we investigated the expression of a set of biomarkers belonging to the 
Akt-PI3K signaling pathway in non-GIST STS patients. In univariate analyses, p-Akt Thr
308
, 
Akt2 and PI3K showed significant unfavorable influence on survival of the whole cohort of 
patients. In addition, PI3K was found to be an independent negative prognostic factor of DSS 
in these patients. We have also elucidated different prognostic effects of Akt phosphorylation 
site, alone and with regard to patient’s gender. Further, the co-expressions of these markers 
and female steroid hormone receptors suggested additive effects or even possible synergisms 
between these different pathways in non-GIST STSs. 
PI3K is, via PDK1 and mTORC2 dependent activation, an upstream regulator of all 
Akt isoforms, and plays an important role in the PI3K/Akt pathway. Its high expression has 
been implicated as an adverse prognostic factor in many types of cancer [190-192]. In STS, 
we observed that PI3K expression was a significant independent indicator of shorter DSS.  
Being a promoter of cell survival, Akt1 has been regarded as a major factor in many 
types of cancer [145-147]. The majority of studies agree on negative prognostic impact of Akt 
expression [149-151], while there are several reports demonstrated an opposite action of Akt 
[152,153]. The latter studies utilized antibodies against p-Akt Ser
473
, while the former were 
based on p-Akt Thr
308
 expression [150,193]. Al-Saad et al. [179] have recently compared the 
prognostic impact of Akt phosphorylated at both sites and demonstrated that expression of p-
Akt Thr
308
, but not p-Akt Ser
473
, negatively influenced prognosis in patients with non-small 
cell lung cancer. For the whole cohort, we have also found that p-Akt Thr
308 
expression was 
associated with a shorter STS survival in the univariate analyses, while p-Akt Ser
473 
expression had no significance. However, calculated separately for each gender, high 
expression of p-Akt Thr
308 
was a negative prognostic factor particularly for men, in contrast to 
p-Akt Ser
473
, which appeared to be a negative prognosticator exclusively for female patients. 
Such gender diversity prompted us to investigate coexpressions of these markers with ER and 
PgR, which were recently shown to activate PI3K/Akt signalling pathway [194,195].  In our 
study, the prognostic diversity of these factors in men and women was enhanced in the co-
expression profiles: male patients with STSs expressing simultaneously p-Akt Thr
308 
and PgR 






profile was the most unfavorable phenotype. The co-expression of PI3K with both ER and 
PgR showed multiple independent negative impacts on survival in STS patients with the 
phenotypes ER-/PI3K+ in women and PgR+/PI3K+ in men being the least favorable. 
Akt2 has been described mostly as a contributor of the insulin signaling pathway, but 
in Akt1 deficient mice it is also proved to substitute, at least partly, the role of Akt1 in growth 
and proliferation [196]. We found Akt2 expression to be associated with significantly shorter 
DSS in univariate analysis. This might be explained by the extra-endocrine function of Akt2 
[196].  
Le Page et al. reported that nuclear Akt1 and Akt2 expression significantly correlated 
with favorable outcome in 63 prostate cancer patients, while cytoplasmic Akt1 expression 
correlated with a higher risk of postoperative prostate-specific antigen (PSA) recurrence and 
shorter PSA recurrence interval [197]. In the present study, we were able to find such 
dependence only for nuclear p-Akt Thr
308 
expression, which proved to be prognostically 
favorable compared to cytoplasmic and especially mixed cytoplasmic and nuclear location.  
The exact mechanisms by which Akt phosphorylation site and combined Akt/PI3K 
and steroid hormone receptors coexpression influence on intracellular signaling cannot be 
elucidated by translational studies. The findings may, however, indicate that these factors are 





6. CONCLUSIONS AND IMPLICATIONS FOR FURTHER RESEARCH 
We have investigated three sets of markers augmenting tumor growth, proliferation 
and dedifferentiation in non-GIST STS patients. Several markers and also interesting co-
expressions proved to be independent prognostic factors. Although the precise molecular 
interactions resulting in STS tumor cell dedifferentiation and proliferation are still unclear, 
our findings may help to identify a subgroup of patients with aggressive tumors which require 
adjuvant therapy.  
Moreover, the biomarkers indicating such aggressiveness can represent molecular 
targets with the future development of small-molecule targeted therapy. PI3/Akt pathway 
components belong to the family of serine-threonine kinases, which are comprehended as 
“drugable” [148], and it was already shown effect of such Akt targeted agents on several 
subtypes of sarcomas in vitro [198,199]. ER and PgR positivity, found to be surprisingly 
common in STSs could possibly identify patients who may have benefit from endocrine 
therapy.  
TMA and IHC have proven to be reliable and feasible methods for biomarker studies 
on tissues. While these methods might not be the most novel, they are well-proven and highly 
reliable when one takes into account their limitations. Our group will continue to conduct 
TMA and IHC studies on non-GIST STSs. We would particularly like to explore factors 
responsible for TGF-β modulation, such as, matrix metalloproteinases, integrins, angiogenic 
and inflammatory agents as well the isoforms and specific receptor of this enigmatic growth 
factor. This also concerns ER and PgR isotypes. 
In addition we have started to measure proliferation-related micro-RNAs by in situ 
hybridization in paraffinized tissue from non-GIST STS patients. We hope to further elucidate 
prognostic factors in non-GIST STS patients as well as seek further knowledge on the impact 
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Figure 1E. Histologic classification of soft tissue tumors. From Weiss SW, Goldblum R: Enzinger & 
Weis's Soft Tissue Tumors, 5th edn. Philadelphia: Mosby, Elseiver Inc; 2008. Permission obtained 
from Elseiver Inc. 
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